Japan has taken an important step in medical science with a new treatment for Parkinson’s disease. Researchers have developed a stem-cell-based therapy that aims to replace damaged brain cells responsible for producing dopamine. The treatment has received conditional approval in Japan and could offer a new option for people living with Parkinson’s disease.

The therapy was developed through research led by Kyoto University. It uses special cells made from induced pluripotent stem cells, also known as iPS cells. These cells are designed to develop into dopamine-producing neurons and help improve movement problems caused by the disease.

What Is Parkinson’s Disease?

Parkinson’s disease is a brain disorder that affects a person's ability to control body movements. It develops when certain brain cells stop working properly or die. These cells normally produce dopamine, a chemical that helps control movement.

When dopamine levels become low, people may experience shaking hands, stiff muscles, slow movements and problems with balance. The condition can also affect daily activities such as walking, writing and speaking.

There are medicines that help control these symptoms, but they do not replace the damaged brain cells. This is why researchers have been looking for new ways to treat the condition.

How Does Japan's New Stem Cell Treatment Work?

The new therapy uses induced pluripotent stem cells, which are special cells that can develop into different types of cells in the body.

Researchers at Kyoto University used these stem cells to create dopamine-producing neuron precursor cells. These cells were then transplanted into both sides of the patients' brains.

The transplant was carried out in an area called the putamen, which plays an important role in controlling movement. The main aim was to help the brain produce dopamine again by allowing the transplanted cells to develop into working dopamine-producing neurons.

The treatment was tested using two different doses. Patients in the low-dose group received around 2.1 to 2.6 million cells in each side of the brain, while those in the high-dose group received around 5.3 to 5.5 million cells per side.

What Were the Results of the Clinical Trial?

The clinical trial included seven patients between the ages of 50 and 69. Researchers monitored them for 24 months to study the safety and possible benefits of the treatment.

Six patients were included in the main effectiveness evaluation. Four of them showed improvements in motor symptoms, while five showed improvements in their movement scores when taking their regular Parkinson's medication.

The researchers also found increased dopamine activity in the treated areas of the brain. Brain scans did not show abnormal growth of the transplanted cells.

No serious adverse events were reported during the study. However, researchers recorded 73 mild-to-moderate adverse events among the seven patients. This means the treatment still needs careful monitoring.

The complete findings were published in the scientific journal Nature on April 16, 2025.

Japan Grants Approval to the New Treatment

After studying the clinical trial results, Japan took another major step towards making this treatment available.

On March 6, 2026, Japan granted conditional and time-limited approval to the therapy. It is named AMCHEPRY and is also known by its generic name, raguneprocel.

The treatment was developed by Sumitomo Pharma with support from Kyoto University researchers and RACTHERA. It is intended for Parkinson's patients whose motor symptoms do not respond well enough to existing medicines, including treatments containing levodopa.

This approval is important because AMCHEPRY became the world's first approved regenerative medicine product based on iPS cells.

However, the approval comes with certain conditions. The company must continue studying the treatment after its launch and collect more information about its safety and effectiveness before seeking full approval.

Readers can find more information in the official announcement by Sumitomo Pharma and RACTHERA.

First Transplant Surgeries Begin in Japan

The treatment has now moved beyond the approval stage. Kyoto University Hospital announced on October 30, 2026, that it had started transplant surgeries using AMCHEPRY.

The first reported patient was a woman in her 50s who underwent the procedure in October. According to the hospital, her recovery after surgery was good and she had already been discharged.

Doctors will continue to monitor her condition to understand how well the transplanted cells work and whether the treatment provides lasting benefits.

The hospital has shared this update through its official announcement about the first transplant surgeries.

What Does This Mean for Parkinson's Patients?

The development could bring a new treatment option for people who do not get enough relief from existing Parkinson's medicines.

Most current treatments focus on managing symptoms. This new approach is different because it aims to replace some of the damaged cells responsible for producing dopamine.

If further studies confirm its benefits, the treatment could change how doctors manage Parkinson's disease in the future.

However, it is important to understand that this is not a confirmed cure. The clinical trial involved a small number of patients, and researchers still need more information about its long-term results.

Conclusion

Japan's new stem-cell-based treatment is an important development in the field of regenerative medicine. The clinical trial showed improvements in movement symptoms among several patients, and the treatment has now received conditional approval.

With the first transplant surgeries already underway, researchers will have more opportunities to study its effects in real-world medical settings.

Although there is still a long way to go, this development has given fresh hope to people living with Parkinson's disease and their families.